文献速递流行病学与生物统计真实世界研究与卫生经济

疫苗对SARS-CoV-2感染和COVID-19疾病有效性的持续时间:系统综述与元回归分析结果

Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.
PubMed 文献 · Lancet · 2022-02-23

该系统综述与元回归分析检索2021年6月17日至12月2日文献,纳入18项研究、78项疫苗特异性评价,评估全程接种后1-6个月疫苗有效性变化。结果显示针对感染的疫苗有效性平均下降21.0个百分点,针对有症状COVID-19下降24.9个百分点,针对重症下降10.0个百分点,但81%的重症有效性估计仍大于70%。

要点

  • 全程接种后1至6个月,针对SARS-CoV-2感染的疫苗有效性平均下降21.0个百分点(95%CI 13.9-29.8)。
  • 针对有症状COVID-19的疫苗有效性平均下降24.9个百分点(95%CI 13.4-41.6)。
  • 针对重症COVID-19的疫苗有效性平均下降10.0个百分点(95%CI 6.1-15.4),多数估计仍大于70%。

核心结论

  • 针对重症的COVID-19疫苗有效性仍保持较高水平,尽管全程接种后6个月时有所下降。
  • 针对感染和有症状疾病的疫苗有效性在6个月时下降约20-30个百分点。
  • 疫苗有效性下降可能至少部分由免疫衰减引起,但不能排除偏倚影响。
  • 评估6个月之后的疫苗有效性对更新COVID-19疫苗政策至关重要。

研究设计与样本

  • 系统综述与元回归分析,检索2021年6月17日至12月2日的预印本和同行评议文章数据库。
  • 纳入COVID-19疫苗效力的随机对照试验和疫苗有效性的观察性研究。
  • 从13744项筛选中,310项全文审查,最终纳入18项研究,所有研究均在奥密克戎变异株广泛传播前开展。
  • 采用随机效应元回归估计全程接种后1-6个月疫苗效力或有效性的平均变化。
  • 共纳入78项疫苗特异性效力或有效性评价:辉瑞-BioNTech-Comirnaty n=38;Moderna-mRNA-1273 n=23;Janssen-Ad26.COV2.S n=9;AstraZeneca-Vaxzevria n=8。

主要发现

  • 针对SARS-CoV-2感染,全程接种后1至6个月疫苗效力或有效性在所有年龄人群中平均下降21.0个百分点(95%CI 13.9-29.8),在老年人中下降20.7个百分点(95%CI 10.2-36.6)。
  • 针对有症状COVID-19,疫苗效力或有效性在所有年龄人群中平均下降24.9个百分点(95%CI 13.4-41.6),在老年人中下降32.0个百分点(95%CI 11.0-69.0)。
  • 针对重症COVID-19,疫苗效力或有效性在所有年龄人群中平均下降10.0个百分点(95%CI 6.1-15.4),在老年人中下降9.5个百分点(95%CI 5.7-14.6)。
  • 针对重症的疫苗效力或有效性估计中,81%在随时间推移后仍大于70%。
  • 偏倚风险:3项研究为低风险,8项为中等风险,7项为严重风险。

关键数值与推荐

  • 针对感染的疫苗效力或有效性下降:所有年龄21.0个百分点(95%CI 13.9-29.8),老年人20.7个百分点(95%CI 10.2-36.6)。
  • 针对有症状COVID-19的疫苗效力或有效性下降:所有年龄24.9个百分点(95%CI 13.4-41.6),老年人32.0个百分点(95%CI 11.0-69.0)。
  • 针对重症COVID-19的疫苗效力或有效性下降:所有年龄10.0个百分点(95%CI 6.1-15.4),老年人9.5个百分点(95%CI 5.7-14.6)。
  • 81%的重症疫苗效力或有效性估计在随时间推移后仍大于70%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有纳入研究均在奥密克戎变异株开始广泛传播之前开展。
  • 偏倚风险:3项研究为低风险,8项为中等风险,7项为严重风险。
  • 疫苗有效性下降可能至少部分由免疫衰减引起,但不能排除偏倚影响。
  • 评估6个月之后的疫苗有效性对更新COVID-19疫苗政策至关重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Knowing whether COVID-19 vaccine effectiveness wanes is crucial for informing vaccine policy, such as the need for and timing of booster doses. We aimed to systematically review the evidence for the duration of protection of COVID-19 vaccines against various clinical outcomes, and to assess changes in the rates of breakthrough infection caused by the delta variant with increasing time since vaccination. METHODS: This study was designed as a systematic review and meta-regression. We did a systematic review of preprint and peer-reviewed published article databases from June 17, 2021, to Dec 2, 2021. Randomised controlled trials of COVID-19 vaccine efficacy and observational studies of COVID-19 vaccine effectiveness were eligible. Studies with vaccine efficacy or effectiveness estimates at discrete time intervals of people who had received full vaccination and that met predefined screening criteria underwent full-text review. We used random-effects meta-regression to estimate the average change in vaccine efficacy or effectiveness 1-6 months after full vaccination. FINDINGS: Of 13 744 studies screened, 310 underwent full-text review, and 18 studies were included (all studies were carried out before the omicron variant began to circulate widely). Risk of bias, established using the risk of bias 2 tool for randomised controlled trials or the risk of bias in non-randomised studies of interventions tool was low for three studies, moderate for eight studies, and serious for seven studies. We included 78 vaccine-specific vaccine efficacy or effectiveness evaluations (Pfizer-BioNTech-Comirnaty, n=38; Moderna-mRNA-1273, n=23; Janssen-Ad26.COV2.S, n=9; and AstraZeneca-Vaxzevria, n=8). On average, vaccine efficacy or effectiveness against SARS-CoV-2 infection decreased from 1 month to 6 months after full vaccination by 21·0 percentage points (95% CI 13·9-29·8) among people of all ages and 20·7 percentage points (10·2-36·6) among older people (as defined by each study, who were at least 50 years old). For symptomatic COVID-19 disease, vaccine efficacy or effectiveness decreased by 24·9 percentage points (95% CI 13·4-41·6) in people of all ages and 32·0 percentage points (11·0-69·0) in older people. For severe COVID-19 disease, vaccine efficacy or effectiveness decreased by 10·0 percentage points (95% CI 6·1-15·4) in people of all ages and 9·5 percentage points (5·7-14·6) in older people. Most (81%) vaccine efficacy or effectiveness estimates against severe disease remained greater than 70% over time. INTERPRETATION: COVID-19 vaccine efficacy or effectiveness against severe disease remained high, although it did decrease somewhat by 6 months after full vaccination. By contrast, vaccine efficacy or effectiveness against infection and symptomatic disease decreased approximately 20-30 percentage points by 6 months. The decrease in vaccine efficacy or effectiveness is likely caused by, at least in part, waning immunity, although an effect of bias cannot be ruled out. Evaluating vaccine efficacy or effectiveness beyond 6 months will be crucial for updating COVID-19 vaccine policy. FUNDING: Coalition for Epidemic Preparedness Innovations.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022. PMID: 35202601. doi:10.1016/S0140-6736(22)00152-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。